Tag Archives: Novartis

Patent Evergreening in India: Response from the Other Side

Plant

Thank you Adriana for commenting on my article Patent “Ever-Greening”: Novartis Confronts Patent Myth in India.  Before I respond, here is your full comment: Adriana says: While patients in India may still be able to access a generic form of off-patent imatinib mesylate (Glivec) if Novartis wins their legal challenge (because this “original form” was never patented in India due to India’s patent law not allowing product patents on medicines prior to 2005), a legal Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patent “Ever-Greening”: Novartis Confronts Patent Myth in India

Pine

India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug from receiving a patent unless the new form is significantly more effective than the previously-known form. This provision aims to accomplish one task: stop patent “ever-greening.”  This issue has risen to prominence lately as the New York Times reports on the Novartis suit challenging patent ever-greening requirements in India’s Supreme Court. So what is patent ever-greening?  Opponents claim that corporations Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

Scientific American on BRIC’s IP Environment

Scientific American World View issued a special report at this year’s 2011 BIO International Convention that had several references to IP protections around the world but focused particularly on the BRIC countries (Brazil, Russia, India, and China).  See below for interesting takes on the IP environment in each country. China: Patently Ambiguous asserts that while “China’s intellectual property environment remains challenging at best” several involved on the ground in China believe that “there should be Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,